{"log_id": 3104452381070528425, "direction": 0, "words_result_num": 36, "words_result": [{"probability": {"variance": 0, "average": 0.99981, "min": 0.99981}, "location": {"width": 29, "top": 34, "height": 28, "left": 1199}, "words": "食"}, {"probability": {"variance": 0.004985, "average": 0.73598, "min": 0.665378}, "location": {"width": 49, "top": 71, "height": 32, "left": 1190}, "words": "芍品"}, {"probability": {"variance": 0, "average": 0.99685, "min": 0.99685}, "location": {"width": 38, "top": 111, "height": 36, "left": 1187}, "words": "附"}, {"probability": {"variance": 9e-06, "average": 0.997932, "min": 0.991772}, "location": {"width": 117, "top": 169, "height": 26, "left": 227}, "words": "不良反应”)"}, {"probability": {"variance": 7.5e-05, "average": 0.997777, "min": 0.947813}, "location": {"width": 810, "top": 218, "height": 27, "left": 247}, "words": "在TNF抑制剂的临床试验中,与对照组相比TNF抑制剂治疗患者出现淋巴瘤的病"}, {"probability": {"variance": 0.000233, "average": 0.996503, "min": 0.90423}, "location": {"width": 839, "top": 268, "height": 28, "left": 204}, "words": "例较多,但较为罕见,且安慰剂治疗患者的随访期比TNF抑制剂治疗患者的随访期短"}, {"probability": {"variance": 0.000167, "average": 0.996995, "min": 0.91917}, "location": {"width": 850, "top": 318, "height": 29, "left": 204}, "words": "此外,长期处于高活性炎症疾病状态的类风湿关节炎患者的淋巴瘤风险增加,从而使风"}, {"probability": {"variance": 4.6e-05, "average": 0.998171, "min": 0.958936}, "location": {"width": 855, "top": 369, "height": 28, "left": 201}, "words": "险评估更为复杂。就目前所知情况,不能排除TNF抑制剂治疗患者出现淋巴瘤或其他"}, {"probability": {"variance": 2e-06, "average": 0.998757, "min": 0.995224}, "location": {"width": 161, "top": 417, "height": 27, "left": 200}, "words": "恶性肿瘤的风险"}, {"probability": {"variance": 0.000307, "average": 0.995164, "min": 0.894116}, "location": {"width": 810, "top": 467, "height": 29, "left": 245}, "words": "曾报告采用TNF拮抗剂(包括依那西普)治疗的患者产生非恶性黑色素瘤皮肤癌"}, {"probability": {"variance": 0.000106, "average": 0.995562, "min": 0.952769}, "location": {"width": 841, "top": 515, "height": 30, "left": 215}, "words": "(NMSC)。在依那西普的临床试验中综合对照部分的结果发现,与对照组相比依那西"}, {"probability": {"variance": 0.00604, "average": 0.978514, "min": 0.533814}, "location": {"width": 858, "top": 565, "height": 30, "left": 197}, "words": "普治疗组患者产生NMSC的病例较多,尤其在银屑病患者。推荐所有患NMSC风险增"}, {"probability": {"variance": 0, "average": 0.999251, "min": 0.998185}, "location": {"width": 320, "top": 614, "height": 29, "left": 197}, "words": "高的患者进行周期性的皮肤检查"}, {"probability": {"variance": 0.000112, "average": 0.995692, "min": 0.939386}, "location": {"width": 815, "top": 664, "height": 29, "left": 240}, "words": "在使用TNF-拮抗剂(包括依那西普)治疗的儿童和青少年患者中有致命恶性肿瘤"}, {"probability": {"variance": 0.002337, "average": 0.990907, "min": 0.701113}, "location": {"width": 837, "top": 710, "height": 30, "left": 214}, "words": "特别是何杰金氏和非何杰金氏淋巴瘤)的报告。多数患者接受了免疫抑制剂的联合冶"}, {"probability": {"variance": 0, "average": 0.99934, "min": 0.99934}, "location": {"width": 22, "top": 764, "height": 23, "left": 192}, "words": "疗"}, {"probability": {"variance": 0.02659, "average": 0.888083, "min": 0.608316}, "location": {"width": 96, "top": 809, "height": 27, "left": 190}, "words": "疫苗接种"}, {"probability": {"variance": 2e-06, "average": 0.999127, "min": 0.99187}, "location": {"width": 815, "top": 860, "height": 28, "left": 236}, "words": "依那西普治疗过程中严禁使用活疫苗。尚无接受依那西普治疗的患者由于接受活疫"}, {"probability": {"variance": 0.000141, "average": 0.997035, "min": 0.924349}, "location": {"width": 860, "top": 909, "height": 28, "left": 189}, "words": "苗而发生二次传播感染的资料。一项双盲、安慰剂对照的随机临床试验中,184例成年"}, {"probability": {"variance": 2e-06, "average": 0.999204, "min": 0.992871}, "location": {"width": 861, "top": 956, "height": 29, "left": 189}, "words": "银屑病关节炎患者在第4周接受了多价肺炎球菌多糖疫苗,多数接受依那西普治疗的银"}, {"probability": {"variance": 3e-06, "average": 0.999157, "min": 0.990468}, "location": {"width": 865, "top": 1004, "height": 28, "left": 186}, "words": "屑病性关节炎患者能对肺炎球菌多糖疫苗产生有效的B细胞免疫应答,但是与未接受依"}, {"probability": {"variance": 6e-05, "average": 0.99802, "min": 0.951711}, "location": {"width": 864, "top": 1052, "height": 29, "left": 186}, "words": "那西普治疗的患者比较,总滴度略低,但少数患者滴度增加2倍,但其临床意义尚不明"}, {"probability": {"variance": 0, "average": 0.999879, "min": 0.999879}, "location": {"width": 23, "top": 1105, "height": 24, "left": 186}, "words": "确"}, {"probability": {"variance": 1e-06, "average": 0.999123, "min": 0.997605}, "location": {"width": 144, "top": 1150, "height": 30, "left": 186}, "words": "自身抗体形成"}, {"probability": {"variance": 0.022621, "average": 0.904698, "min": 0.644379}, "location": {"width": 154, "top": 1134, "height": 55, "left": 681}, "words": "总海医药"}, {"probability": {"variance": 0.001525, "average": 0.983595, "min": 0.811163}, "location": {"width": 637, "top": 1170, "height": 63, "left": 227}, "words": "依那西普治疗可能会产生自身抗体(参见“不良反应)。"}, {"probability": {"variance": 1e-06, "average": 0.999122, "min": 0.998107}, "location": {"width": 118, "top": 1247, "height": 29, "left": 183}, "words": "血液学反应"}, {"probability": {"variance": 5e-06, "average": 0.999078, "min": 0.986671}, "location": {"width": 825, "top": 1297, "height": 29, "left": 224}, "words": "接受依那西普治疗的患者罕见报告出现全血细胞减少,非常罕见报告出现再生障碍"}, {"probability": {"variance": 2e-06, "average": 0.999091, "min": 0.993515}, "location": {"width": 870, "top": 1345, "height": 29, "left": 179}, "words": "性贫血,一些导致死亡。有血恶液质病史的患者使用依那西普治疗时,应谨慎使用。使"}, {"probability": {"variance": 5e-06, "average": 0.99855, "min": 0.988346}, "location": {"width": 872, "top": 1395, "height": 28, "left": 178}, "words": "用依那西普过程中,所有出现血恶液质或感染征兆(比如持续发热、咽喉痛、淤血、出"}, {"probability": {"variance": 2.6e-05, "average": 0.998338, "min": 0.968355}, "location": {"width": 870, "top": 1442, "height": 30, "left": 179}, "words": "血、苍白)的患者,应立即寻求医疗指导。以上患者应当立即进行包括全血细胞计数在"}, {"probability": {"variance": 1e-06, "average": 0.99932, "min": 0.99526}, "location": {"width": 557, "top": 1493, "height": 28, "left": 177}, "words": "内的检查;如果确诊血恶液质,必须停止使用依那西普"}, {"probability": {"variance": 0.001647, "average": 0.977493, "min": 0.867999}, "location": {"width": 282, "top": 1542, "height": 27, "left": 177}, "words": "中枢神经系统(CNS)疾病"}, {"probability": {"variance": 3.8e-05, "average": 0.99816, "min": 0.963548}, "location": {"width": 816, "top": 1590, "height": 28, "left": 222}, "words": "罕见报告依那西普治疗的患者出现中枢神经系统脱髓鞘病变(参见“不良反应”)"}, {"probability": {"variance": 0.000117, "average": 0.990957, "min": 0.968221}, "location": {"width": 161, "top": 1639, "height": 26, "left": 177}, "words": "版本号:20090118"}, {"probability": {"variance": 7.2e-05, "average": 0.994499, "min": 0.973457}, "location": {"width": 178, "top": 1637, "height": 28, "left": 787}, "words": "第12页共31页"}], "language": 3}